Latest news with #BIO
Business Journals
2 days ago
- Business
- Business Journals
How the BIO International Convention allows the United Kingdom to show it's open for business
The annual BIO International conference is large. Very large, with around 20,000 leaders from the global biotech ecosystem in attendance. So it's no surprise that for years, the UK's Department for Business and Trade (DBT) and its partner, the Association of the British Pharmaceutical Industry, have hosted a UK Pavilion featuring UK innovators in the biotech industry, research and development. "BIO is a big conference; it's important for us to be there to show the UK is open for business as every country you can think of is represented,' says Karl Davison, senior business development manager at the National Institute for Health and Care Research (NIHR), one of the organizations on the UK Pavillion. The UK Pavilion isn't just open for business. It's a one-stop shop, making it as easy as possible for potential U.S. and global partners to make fruitful UK connections and gain insight across UK biotech's broad ecosystem of innovation and resources. "Our collaboration with the DBT on the UK Pavilion is central to our global engagement strategy,' says James Richards, Ph.D., NIHR's head of business development. 'It allows international companies to access a uniquely streamlined experience: in a single, highly productive meeting, they can speak to UK experts on regulation, life sciences policy, how to set up a commercial base in the UK — and with the NIHR about our world-class research infrastructure. Together, we can provide a comprehensive introduction to the UK's life sciences ecosystem." Making connections Since 2015, 39 export partnerships, totalling nearly $300 million, have resulted from DBT support at the yearly BIO Conference. So, companies like hVIVO, a full-service Contract Research Organization and a global leader in human challenge trials, will be returning to the UK Pavilion with DBT, as will Merxin Ltd, a UK biotech research company specializing in dry powder and soft mist inhalers. "We had an extraordinary run last year at BIO International in San Diego," says Philippe Rogueda, chief business officer and chief operating officer at Merxin Ltd. "BIO is one of the most exciting events for new molecule therapies investment in North America, probably in the world. We met about 250 people and had 40 arranged meetings with a range of companies, which were in different stages of clinical development, as well as investors. Being part of the UK Pavilion with the UK Department of Business and Trade is great; there is a real benefit to having a physical presence at BIO." William Ward, business development manager at Merxin Ltd, adds: "You get the chance to meet some of these really innovative, emerging biotechs as well as big pharmas at BIO, and the risk appetite is there. Last year, we had several conversations with companies who maybe hadn't considered inhalation as their typical route of administration but were very keen to understand how they could utilize Merxin's devices to advance their therapies. That type of mindset and innovation is where some great partnerships can be formed." The benefits go both ways. "The ability to have face-to-face conversations makes for an impactful conference,' says Davison. 'Sometimes companies don't realize how much we can do to support them and, if we can provide them with a golden nugget of information, it makes the UK a stronger prospect for their next clinical trial." The UK-U.S. partnership: Greater together With its world-leading research institutions, innovative biotech companies, and commitment to science and technology advancement, the UK has a strong offer, including: The UK tech sector is one of only three nations valued at over $1 trillion, making it the third largest tech ecosystem in the world behind only the U.S. and China In 2023, UK startups raised the most venture capital in Europe The UK is home to four of the top 10 global universities for life sciences and medicine and leverages the expertise of the National Health Service (NHS), which offers an unmatched wealth of health data for innovative research The UK ranks third globally for elite artificial intelligence (AI) talent, number of AI startups, inward investment into AI and government readiness for AI adoption — with a sector valued at $92 billion. As global leaders in science and technology, the U.S. and UK make natural partners in R&D. In fact, more than 10% of U.S. foreign R&D investment goes into the UK, the largest share of any country where U.S. businesses invest in research and innovation. And following the landmark economic deal between the U.S. and UK earlier this year, the UK is working toward building a broad and deep a UK-U.S. science and technology partnership through which these science-rich nations will collaborate in biotech and life sciences, as well as quantum computing, nuclear fusion, and aerospace. If you're a U.S. investor or company that would like to learn more about how partnering with UK biotech can grow your business, stop by the UK Pavilion at BIO (Hall A, stand 765), or contact a DBT sector specialist near you who can connect you with UK suppliers and investment opportunities. Email us to learn more. The UK's Department for Business and Trade is an economic growth department. We ensure fair, competitive markets at home, secure access to new markets abroad, and support businesses to invest, export, and grow. Our priorities are the Industrial Strategy, Make Work Pay, the Trade Strategy and the Plan for Small Business.
Business Wire
2 days ago
- Business
- Business Wire
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a global branded film series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier series explores how biotechnology can be used effectively to address urgent challenges the world faces. As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal storage disorder. 'This film demonstrates the hardships and challenges that people living with MPS II face on a daily basis from the perspective of a family affected by this devastating and life-limiting disease,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'We are honored to participate in this important video series to shine a spotlight on MPS II and increase awareness worldwide about this debilitating rare disease for which patients desperately need new treatment options. This impactful story is a great illustration of how collaborating with patient communities drives progress. We are committed to supporting the MPS II patient community, and we look forward to advancing our investigational therapy for people living with MPS II.' The Next Frontier series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection. The series debuted at the BIO International Convention, taking place from June 16-19, 2025. Watch the JCR film here, and view the full The Next Frontier series here. About The Next Frontier Series The Next Frontier is a global branded film series presented by Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions, and it explores how biotechnology can be used effectively to address urgent challenges the world faces. The series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection and features the tools that help the public not just understand biotech but believe in its potential. If the future depends on science, it also depends on the stories we tell. About Biotechnology Innovation Organization (BIO) BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services, worldwide. BIO members are at the forefront of researching and developing innovative biotechnologies across healthcare, agriculture, industry, and the environment. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO is helping to drive a revolution that aims to cure patients, protect our climate, and nourish humanity. About Mucopolysaccharidosis Type II (Hunter Syndrome) Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Yahoo
2 days ago
- Business
- Yahoo
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
- Story Highlights Severity and Impact of MPS II, a Rare, Life-Threatening Lysosomal Storage Disorder - HYOGO, Japan, June 18, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a global branded film series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier series explores how biotechnology can be used effectively to address urgent challenges the world faces. As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal storage disorder. "This film demonstrates the hardships and challenges that people living with MPS II face on a daily basis from the perspective of a family affected by this devastating and life-limiting disease," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "We are honored to participate in this important video series to shine a spotlight on MPS II and increase awareness worldwide about this debilitating rare disease for which patients desperately need new treatment options. This impactful story is a great illustration of how collaborating with patient communities drives progress. We are committed to supporting the MPS II patient community, and we look forward to advancing our investigational therapy for people living with MPS II." The Next Frontier series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection. The series debuted at the BIO International Convention, taking place from June 16-19, 2025. Watch the JCR film here, and view the full The Next Frontier series here. About The Next Frontier SeriesThe Next Frontier is a global branded film series presented by Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions, and it explores how biotechnology can be used effectively to address urgent challenges the world faces. The series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection and features the tools that help the public not just understand biotech but believe in its potential. If the future depends on science, it also depends on the stories we tell. About Biotechnology Innovation Organization (BIO)BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services, worldwide. BIO members are at the forefront of researching and developing innovative biotechnologies across healthcare, agriculture, industry, and the environment. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO is helping to drive a revolution that aims to cure patients, protect our climate, and nourish humanity. About Mucopolysaccharidosis Type II (Hunter Syndrome)Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far. About JCR Pharmaceuticals Co., Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@
Politico
3 days ago
- Business
- Politico
BIO chair: U.S. has a ‘crisis' on drug costs
Driving The Day NEW BIO CHAIR'S POLICY TAKE — The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump's second term. One of its chief lobbying arms is gearing up to take them on. Ahead of the Biotechnology Innovation Organization's annual convention this week in Boston, Genentech's Fritz Bittenbender — who was elected Monday as the group's board chair — chatted with Lauren about BIO's priority issues, distrust in science and medical institutions and its approach to geopolitical engagement. Pros can read the full Q&A, but here are some highlights and outtakes: An 'existential policy crisis': Bittenbender used the term to refer to debates around 'intellectual property, how do you pay for medicines, what kind of investments are we going to make at early-stage research' — all of which bring to mind Trump administration priorities like the most-favored-nation approach to bringing down drug prices and limiting National Institutes of Health spending on indirect costs in university research. 'We have a lot of sound-bite policy happening right now, and [most-favored-nation is] a great example of that,' he said, adding that the U.S. health system works much differently from those in allied European countries, often held up as examples of cheaper markets. How industry can combat distrust in science: Biotechs need to do a better job of communicating the benefits they bring to patients, and they need policymakers' help, Bittenbender said. 'Working with policymakers, and … bringing as much transparency to our industry as we possibly can — using real-world data and digital analytics more effectively to understand postmarketing studies of products on the market and being transparent about that,' he said. Federal job cuts: Regulatory uncertainty is an 'existential threat' to the industry amid the massive downsizing and restructuring of the Department of Health and Human Services, Bittenbender said. 'If it's going to take 10 or 15 years to bring a product to the market and $1 [billion] to $2 billion to do that, that's a significant investment over a long-term period. And for investors to want to do that, they have to know that there's a certain regulatory environment,' he said. 'They have to know that regulatory timelines are going to be met or exceeded.' The tariff threat: 'Our industry is a national security imperative for the country, and that means having essential medicines that patients really need manufactured here,' Bittenbender said. 'Hopefully, we won't see tariffs on the pharmaceutical industry, and we work in other ways to get manufacturing into the United States and to ensure that essential medicines that we need in times of emergency or pandemic are sourced from a place that we trust and that we know we can get them,' he added. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. NPR reports on how music therapy can help cancer patients manage their stress and symptoms. Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA SECOND DMD DRUG DEATH — A second patient with Duchenne muscular dystrophy has died after taking Sarepta Therapeutics' Elevidys gene therapy, the company said, prompting a reevaluation of the drug's treatment protocol. The death occurred in a 15-year-old nonambulatory individual enrolled in the company's randomized, placebo-controlled trial intended to confirm the drug's benefit in patients who can't walk under the FDA's accelerated approval pathway. A company official said the latest death shares 'some similarities to the previous' death of a teenage boy earlier this year; both fatalities were due to acute liver failure, a known side effect of the viral vector gene therapy used in Elevidys. Sarepta said the signal has emerged only in patients who can't walk, which they consider a surrogate for disease progression. Sarepta President and CEO Douglas Ingram said the company wants to meet with the FDA 'as rapidly as possible' to establish a new immunosuppressive regimen for nonambulatory patients. Until that's implemented, the company has paused drug shipments for that population, as well as dosing for its clinical trial, it said. Response: HHS spokesperson Emily Hilliard said the FDA is treating the death 'with the highest level of concern' and 'will take all appropriate regulatory actions to protect patients during our review of gene therapy products.' The FDA is reviewing a cell therapy candidate from Capricor Therapeutics to treat DMD. The target date for a decision is Aug. 31. PDUFA PROBLEMS? KalVista Pharmaceuticals raised some eyebrows late last week after announcing that the FDA had disclosed it would miss its Tuesday PDUFA target for the drug sebetralstat, which is used as therapy for hereditary angioedema, 'due to heavy workload and limited resources.' The rare disorder causes episodes of swelling in various parts of the body and can sometimes be fatal. FDA Commissioner Marty Makary has repeatedly said medical product reviews would continue apace despite thousands of job cuts at the agency, and reviewers were not among the terminated workers. But employees charged with supporting review staff by booking travel and securing supplies were impacted, and drug companies remain concerned about attrition in the remaining workforce. HHS did not comment. In Congress EXPANDED ORPHAN EXEMPTION OUT — The Senate Finance Committee's reconciliation bill strips an effort by the House to expand a Medicare drug price negotiations exemption for orphan drugs to include medicines that treat multiple rare diseases or conditions. The Congressional Budget Office estimated the policy in the House bill would cost the federal government nearly $5 billion over 10 years, a figure groups like AARP and Patients For Affordable Drugs Now used to urge senators to keep the measure out of the Senate bill. But pharmaceutical companies argue the provision would incentivize additional investment in rare-disease drug development as the IRA exemption currently applies to orphan drugs that treat a single rare disease. SANDERS WANTS ACIP INVESTIGATION — Senate HELP ranking member Bernie Sanders (I-Vt.) wants his counterpart to open a bipartisan investigation into the removal of 17 members of the CDC's outside vaccine committee. In his letter to Sen. Bill Cassidy (R-La.), chair of the Health, Education, Labor and Pensions Committee, Sanders asked for 'serious oversight' of HHS Secretary Robert F. Kennedy Jr.'s actions regarding the Advisory Committee for Immunization Practices. 'Secretary Kennedy's reckless decision to fire these non-partisan scientific experts and replace them with ideologues with limited expertise and a history of undermining vaccines will not only endanger the lives of Americans of all ages, it directly contradicts a commitment he made to you before he was confirmed that he would not make any significant changes to this important Committee,' Sanders wrote to Cassidy. A spokesperson for Cassidy did not immediately respond to a request for comment. In the courts PURDUE SETTLEMENT 2.0 — All 50 states and several U.S. territories have agreed to sign onto a $7.4 billion settlement with Purdue Pharma and its principal owners, the Sackler family, that will resolve state and local government claims. 'The local government sign-on and voting solicitation process for this settlement moving forward will be contingent on bankruptcy court approval,' California Attorney General Rob Bonta's office said in a news release. 'A hearing is scheduled on that matter in the coming days.' The settlement ends the Sackler family's control of Purdue and prevents them from selling opioids in the country. Document Drawer The FDA's Psychopharmacologic Drugs Advisory Committee will meet on July 18 to discuss Otsuka Pharmaceutical's supplemental new drug application to approve Rexulti to treat adults with post-traumatic stress disorder in combination with sertraline. The FDA published final guidance outlining recommendations for generic drugmakers on how to submit a pre-submission facility correspondence that can be used to help the agency begin site assessments in advance of submitting an abbreviated new drug application. WHAT WE'RE READING The 17 dismissed members of the CDC's vaccine advisory panel published an op-ed in JAMA, saying their abrupt dismissal last week 'undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence.' HHS awarded an Arizona law firm $150,000 for its expertise on the Vaccine Injury Compensation Program, NOTUS' Margaret Manto reports, suggesting it's considering policy changes to the 40-year-old system.
Business Journals
13-06-2025
- Business
- Business Journals
Five things: BIO in Boston, 'Loganing,' Petri Dish and Best Places to Work rankings
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Friday, and one more thing to know: Tomorrow marks yet another Saturday with rain in the forecast. 1. Forget 'Storrowing.' Massport deals with 'Loganing' MassPort is taking steps to address an uptick in "too-tall" truck strikes on road signs and overpasses at Logan International Airport, Isabel Hart reports. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events 2. BIO is nigh upon us BIO International, the global convention for life sciences companies, investors, partners and the state and national economic development officials wooing them, is arriving in Boston starting on Monday. Hannah Green has all you need to know about what it means to host this major trade show, and spoke with one of the original architects of the Massachusetts life sciences industry. 3. Alnylam, GSK, Vertex pledge Mass. jobs for tax incentives Green also reports that 33 life sciences companies are slated to receive $29.9 million in tax incentives in exchange for creating over 1,500 new jobs in Massachusetts. Do you like the Five Things? Make sure to subscribe — free — to our Morning Edition emails so you have it in your inbox each day. 4. Boston vaccine developer acquired for $1.25B And because she's not busy enough, Green also reports that CureVac NV, whose U.S. headquarters is in Boston, is being acquired by BioNTech in a deal valued at $1.25 billion. 5. How small businesses can use AI Small businesses are learning to put AI to work as an extra pair of hands through a partnership with a local nonprofit led by a Boston University researcher and the Black Economic Council of Massachusetts, Eli Chavez reports. What else you need to know By the numbers The Petri Dish A spinout from Scorpion Therapeutics debuted with $177 million, Bicara Therapeutics doubled its footprint, and the Mass. Life Sciences Center gave out health equity awards of $50,000 — all in the latest biotech news roundup from Hannah Green. On the radio This morning at 6:45 or 8:45 on GBH Radio's "Morning Edition" you can hear Jess Aloe report the "Boston Business Journal Minute" — a quick highlight of the week's top stories. Not near the radio? Listen here anytime. Listen this Sunday to the New England Business Report, where I will be discussing the news of the week with Kim Carrigan and Joe Shortsleeve. Tune in at 8 a.m. on WRKO-AM 680 or listen here. Quotable 'I feel like the grandmother who sits at the soccer game, and I look out there and I see my little grandchild running up and down the field and scoring goals and being a star player. And nobody knows that that's my grandchild, but I know.' — Susan Windham-Bannister, former head of the Mass. Life Sciences Center, reflecting on the growth of the industry since 2008. Today in history On this day in 1995, Alanis Morissette released her breakthrough album, Jagged Little Pill. (On This Day In Music) Birds I'm seeing Tree Swallow in Belle Isle Marsh, East Boston What's good on WERS-FM Brilliant Mistake, by Elvis Costello What I'm watching Kaos, on Netflix Welcome to the jungle Whether you like Guns N' Roses, or not, you couldn't ignore the jungle theme at last night's 23rd annual Boston Business Journal Best Places to Work ceremony and reception. Stay tuned for photos from the event, which will be posted to our site later today, but for those of you wondering which companies ranked highest in their size category, you can find all the 2025 Best Places to Work here or scroll below for the rankings themselves. As I mentioned, the event was 'jungle-themed,' meaning lots of vegetation, animals and reptiles, stilt-walking giraffes, elephants and lions, and more. We had over 300 nominations this year, and from those, Massachusetts-based employees were surveyed by Quantum Workplace, our longtime data partner, and their responses led us to expand this year's ranking from 80 companies to 100 qualifying as Best Places to Work. If you love your company and think it could be among the top-ranked Best Places to Work, be sure to contact Sean McFadden, our associate editor, research, who will make sure you're included in the survey process next year. PARTING SHOT You know how much I love a wildlife webcam. Well, these researchers are using hidden cameras in the jungles of Central America to get help from the animals themselves in documenting the rainforest's incredible variety of species. Subscribe to the Morning Edition or Afternoon Edition for the business news you need to know, all free. Best Places to Work: Extra Large Companies (500 employees and up) Score Rank Prior Rank Company 1 1 VHB 2 6 Arbella Insurance Group 3 3 Vertex Pharmaceuticals Inc. View this list Best Places to Work: Large Companies (250 to 499 employees) Score Rank Prior Rank Company 1 2 Wasabi Technologies 2 2 CyberArk 3 3 Weston & Sampson View this list Best Places to Work: Medium Companies (100 to 249 employees) Score Rank Prior Rank Company 1 1 SEI - Boston 2 2 RapDev LLC 3 2 J. Calnan & Associates View this list Best Places to Work: Small Companies (50 to 99 employees) Score Rank Prior Rank Company 1 1 Tines 2 3 Ligris + Associates PC 3 3 Your Part-Time Controller LLC View this list
